Linda Palczuk - 15 Sep 2025 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Reporting relationship: Director
Issuer ticker: AVDL
Reported as of: 15 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Sep 2025, 19:54:41 UTC
Prior SEC filing: 31 Jul 2025
Next SEC filing: 12 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jerad G. Seurer, as attorney-in-fact

Key filing fact

Linda Palczuk filed Form 4 for AVADEL PHARMACEUTICALS PLC (AVDL) on 15 Sep 2025.

Key facts

This page summarizes Linda Palczuk's Form 4 filing for AVADEL PHARMACEUTICALS PLC (AVDL).
1 reported transaction and 2 derivative rows are listed below.
Accepted by SEC: 15 Sep 2025, 19:54.

Change

Previous filing in this sequence was filed on 31 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001717580 Primary reporting owner

Palczuk Linda

Relationship: Director
Address: C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND
Signature: /s/ Jerad G. Seurer, as attorney-in-fact
Signature date: 15 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVDL transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: -11,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 15 Sep 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 11,000
Exercise price: $10.83
Footnotes: F1

AVDL holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 11,000
Date: 15 Sep 2025
Ownership: By Trust
Underlying class: Ordinary Shares
Underlying amount: 11,000
Exercise price: $10.83
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.

Footnote F2

On September 15, 2025, the Reporting Person transferred 11,000 options to a revocable trust of which the Reporting Person is trustee.